Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ASKA Pharmaceutical Co Ltd Amends Consolidated Mid-year Outlook for FY 2014


Monday, 28 Oct 2013 02:10am EDT 

ASKA Pharmaceutical Co Ltd announced that it has lowered consolidated mid-year outlook for revenue from JPY 20,800 million to JPY 20,000 million, and raised the outlook for operating profit from JPY 200 million to JPY 700 million, ordinary profit from JPY 350 million to JPY 800 million, net profit from JPY 140 million to JPY 500 million, earnings per share from JPY 5.05 to JPY 18.02 for the fiscal year ending March 2014. The positive profit outlook is mainly due to reduction of sales and administration costs. 

Company Quote

1123.0
1.0 +0.09%
25 Jul 2014